Wave Life Sciences, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Wave Life Sciences, Inc. reported a quarterly adjusted loss of 30 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -32 cents. The mean expectation of twenty analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -38 cents to -28 cents per share.

• Revenue rose 72.9% to $13.16 million from a year ago; analysts expected $4.32 million.

• Wave Life Sciences, Inc.'s reported EPS for the quarter was a loss of 30 cents​.

• The company reported a quarterly loss of $61.91 million.

• Wave Life Sciences, Inc. shares had fallen by 13.2% this quarter and lost 81.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Wave Life Sciences, Inc. is $15.00, about 78.6% above its last closing price of $3.21

This summary was machine generated from LSEG data October 27 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)